Table 2. Results of the univariable and multivariablea analyses for OS.
| Covariates | Univariable analyses | Multivariable analysis | ||
|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |
| DT | 1.02 | 0.91-1.14 | ||
| DT | ||||
| <5 | 0.99 | 0.56-1.76 | ||
| ≥5b | ||||
| Age | 1.04 | 1.00-1.07 | 1.03 | 1.00-1.07 |
| Sex | ||||
| Male Femaleb | 0.71 | 0.41-1.22 | ||
| Histology | ||||
| Adenocarcinomab | ||||
| Squamous cell carcinoma | 1.72 | 0.95-3.13 | ||
| NSCLC otherwise not specified, adenomatous hyperplasia | 1.33 | 0.31-5.71 | ||
| SCLC | 1.01 | 0.43-2.39 | ||
| CCI | ||||
| 0-1 | 0.98 | 0.44-2.18 | ||
| > 2b | ||||
| Treatment | ||||
| Surgery and (neo)adjuvant chemotherapyb | ||||
| Chemotherapy | 1.45 | 0.57-3.71 | 1.43 | 0.56-3.66 |
| Chemotherapy and sequential/concurrent radiotherapy | 6.87 | 2.16-21.85 | 6.34 | 1.99-20.19 |
aAll variables entered together in one block.
bReference group.
Abbreviations: OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; DT, distress thermometer score at first cycle of chemotherapy as a continuous variable; NSCLC, non-small cell lung carcinoma; SCLC, small cell lung carcinoma, CCI, Charlson Comorbidity Index.